Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Suggested Reading
Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE, et al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J Pediatr. 2017;181:12–28.
Aschner JL. New therapies for pulmonary hypertension in neonates and children. Pediatr Pulmonol. 2004;37(Suppl. 26):132–5.
Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959–67.
Atkinson SA. Special nutritional needs of infants for prevention of and recovery from bronchopulmonary dysplasia. J Nutr. 2001;131:942S–6S.
Bancalari E, editor. Bronchopulmonary dysplasia. Semin Perinatol. 2003;8:1–92.
Brunton JA, Saigal S, Atkinson S. Growth and body composition in infants with bronchopulmonary dysplasia up to 3 months corrected age: a randomized trial of a high-energy nutrient-enriched formula fed after hospital discharge. J Pediatr. 1998;133:340–5.
Buzzella B, Claure N, D’Ugard C, Bancalari E. A randomized controlled trial of two nasal continuous positive airway pressure levels after extubation in preterm infants. J Pediatr. 2014;164:46–51.
Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999;340:1005–10.
D’Angio CT, Maniscalco WM. Bronchopulmonary dysplasia in preterm infants: pathophysiology and management strategies. Paediatr Drugs. 2004;6:303–30.
Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology. 2010;98:111–7.
Grier DG, Halliday HL. Corticosteroids in the prevention and management of BPD. Semin Neonatol. 2003;8:83–91.
Kao LC, Durand DJ, McCrea RC, et al. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr. 1994;124:772–81.
Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, et al. Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. J Pediatr. 2017;188:24–34.
Michael Z, Spyropoulos F, Ghanta S, Christou H. Bronchopulmonary dysplasia: an update of current pharmacologic therapies and new approaches. Clin Med Insights Pediatr. 2018;12:1–12.
Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009;154(3):379–84.
O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104:15–21.
Onland W, Offringa M, De Jaegere AP, van Kaam AH. Finding the optimal postnatal dexamethasone regimen for preterm infants at risk of bronchopulmonary dysplasia: a systematic review of placebo-controlled trials. Pediatrics. 2009;123:367–77.
Poets CF, Lorenz L. Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates: current evidence. Arch Dis Child Fetal Neonatal Ed. 2018;103:F285–91.
Reyes Z, Tauscher M, Claure N. Randomized, controlled trial comparing pressure support (PS) + synchronized intermittent mandatory ventilation (SIMV) with SIMV in preterm infants. Pediatr Res. 2004;55:466A.
Schmidt B, Roberts R, Millar D, Kirpalani H. Evidence-based neonatal drug therapy for prevention of bronchopulmonary dysplasia in very-low-birth-weight infants. Neonatology. 2008;93:284–7.
Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012 for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. JAMA. 2015;314(10):1039–51.
SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970–9.
Tyson JE, Wright LL, Oh W, et al. Vitamin a supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999;340:1962–8.
Wardle AJ, Wardle R, Luyt K, et al. The utility of sildenafil in pulmonary hypertension: a focus on bronchopulmonary dysplasia. Arch Dis Child. 2013;98:613–7.
Watterberg KL, Committee on Fetus and Newborn. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics. 2010;126:800–8.
Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004;350:1304–13.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bancalari, E. (2022). Bronchopulmonary Dysplasia: Clinical Management. In: Donn, S.M., Mammel, M.C., van Kaam, A.H. (eds) Manual of Neonatal Respiratory Care. Springer, Cham. https://doi.org/10.1007/978-3-030-93997-7_79
Download citation
DOI: https://doi.org/10.1007/978-3-030-93997-7_79
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-93996-0
Online ISBN: 978-3-030-93997-7
eBook Packages: MedicineMedicine (R0)